<DOC>
	<DOCNO>NCT01131546</DOCNO>
	<brief_summary>This study design compare safety efficacy levamlodipine besylate ( 2.5mg 5mg ) versus amlodipine maleate ( 5mg ) patient mild moderate essential hypertension .</brief_summary>
	<brief_title>Efficacy Safety Levamlodipine Besylate Compared Amlodipine Maleate Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<criteria>Male female outpatient , 1875 Years Patients mild moderate essential hypertension ( define mean BP 2 visit â‰¥140mm/90mmHg , &lt; 180mm/110mmHg ) Written informed consent Patients secondary hypertension Patients severe hypertension Have take drug influence blood pressure study Allergic DHP calcium antagonists Evidence congestive heart failure , unstable angina severe arrhythmia Renal hepatic dysfunction Women take contraceptive pill likely pregnant Participate clinical trial within 3 month prior study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Essential Hypertension</keyword>
	<keyword>Levamlodipine Besylate</keyword>
	<keyword>Amlodipine Maleate</keyword>
</DOC>